Barclays Has Lowered Expectations for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR - Get Free Report) had its price target decreased by research analysts at Barclays from $26.00 to $23.00 in a report released on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price objective would indicate a potential upside of 26.97% from the stock's previous close.

Several other equities analysts have also recently issued reports on AVTR. UBS Group restated a "neutral" rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Raymond James reduced their price objective on Avantor from $29.00 to $26.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their price objective on Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Avantor currently has an average rating of "Moderate Buy" and a consensus price target of $26.15.

Avantor Stock Up 0.4 %

Shares of AVTR stock traded up $0.07 during mid-day trading on Monday, reaching $18.12. 6,265,783 shares of the company were exchanged, compared to its average volume of 5,451,938. Avantor has a fifty-two week low of $17.90 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a market capitalization of $12.33 billion, a P/E ratio of 39.38, a P/E/G ratio of 3.87 and a beta of 1.28. The business's 50 day simple moving average is $21.57 and its 200 day simple moving average is $23.35.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the prior year, the company earned $0.22 earnings per share. Research analysts predict that Avantor will post 0.98 earnings per share for the current year.

Institutional Investors Weigh In On Avantor

A number of hedge funds and other institutional investors have recently modified their holdings of AVTR. MassMutual Private Wealth & Trust FSB raised its stake in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock valued at $26,000 after purchasing an additional 625 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock worth $34,000 after acquiring an additional 830 shares during the period. UMB Bank n.a. acquired a new position in Avantor during the third quarter worth about $49,000. Global Retirement Partners LLC grew its holdings in Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock worth $52,000 after acquiring an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock worth $53,000 after acquiring an additional 835 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.